A corporate VC based in Shanghai, China with a recently established U.S. branch in California manages a $100M fund and typically invests $500K-$1M per company with the ability for acquisition at up to $100M. The fund is particularly seeking U.S.-based companies with innovative technologies to bring to the China market, and supports FDA-approved companies to gain CFDA approval.
The firm is seeking truly innovative medical devices and diagnostics in women’s health (OBGYN), neonatal healthcare, geriatric pregnancy, and other women’s health indications; women and children health-related products or services; life science-related products to be used in the research field; diagnostic kits; and immunotherapy and cell therapy services. The firm is not interested in pharmaceuticals or biotech therapeutics due to the longer development timeline, and particularly seeks late-stage technologies that are near or on-the-market generating revenue. The firm is open to all classes of devices.
The firm is seeking to invest or acquire private companies. Companies with products to be introduced to China is preferred.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org